Avacta Group Plc (OTCMKTS:AVCTF – Get Free Report) was the recipient of a large growth in short interest in October. As of October 30th, there was short interest totaling 234,775 shares, a growth of 2,347,650.0% from the October 15th total of 10 shares. Based on an average daily volume of 36 shares, the short-interest ratio is currently 6,521.5 days.
Avacta Group Price Performance
OTCMKTS AVCTF remained flat at $0.77 on Tuesday. The company’s 50 day moving average price is $0.90 and its 200 day moving average price is $0.92. Avacta Group has a 1-year low of $0.74 and a 1-year high of $1.23.
About Avacta Group
Avacta Group is a UK-based biotechnology company focused on developing cancer therapies. Its proprietary pre|CISION platform is designed to keep drug payloads inactive in circulation and activate them within the tumor environment, with the goal of concentrating treatment at the tumor site. The company’s clinical-stage pipeline includes AVA6000, a doxorubicin prodrug designed to be activated by an enzyme found in many tumors. Avacta has also developed Affimer, an engineered protein-binding technology, and has pursued diagnostic applications alongside its earlier research activities.
See Also
- Five stocks we like better than Avacta Group
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
